Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).

In conclusion, addition of bendamustine to Ven-R/-G increased toxicity without apparent efficacy benefit.
PMID: 33121235 [PubMed - in process]

Source: Haematologica - October 29, 2020 Category: Hematology Authors: Stilgenbauer S, Morschhauser F, Wendtner CM, Cartron G, Hallek M, Eichhorst B, Kozloff MF, Giever T, Lozanski G, Jiang Y, Huang H, Pignataro DS, Schary W, Humphrey K, Mobasher M, Salles G Tags: Haematologica Source Type: research